United States securities and exchange commission logo





                              October 22, 2020

       Nima M. Farzan
       President and Chief Executive Officer
       Kinnate Biopharma Inc.
       11875 El Camino Real, Suite 101
       San Diego, California 92130

                                                        Re: Kinnate Biopharma
Inc.
                                                            Amendment No. 1 to
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted October
16, 2020
                                                            CIK No. 0001797768

       Dear Ms. Farzan:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Draft Registration Statement on Form S-1 submitted October 16, 2020

       Certain Relationships and Related Party Transactions, page 174

   1.                                                   We note your response
to comment 14; however, you have not provided the requested
                                                        information with
respect to Eshelman Ventures, LLC. Please revise.
       General

   2.                                                   Please supplementally
provide us with copies of all written communications, as defined in
                                                        Rule 405 under the
Securities Act, that you, or anyone authorized to do so on your behalf,
                                                        present to potential
investors in reliance on Section 5(d) of the Securities Act, whether or
                                                        not they retain copies
of the communications.
 Nima M. Farzan
Kinnate Biopharma Inc.
October 22, 2020
Page 2

        You may contact Angela Connell at (202) 551-3426 or Julie Sherman at
(202) 551-
3640 if you have questions regarding comments on the financial statements and
related
matters. Please contact Abby Adams at (202) 551-6902 or Celeste Murphy at (202)
551-
3257 with any other questions.



                                                         Sincerely,
FirstName LastNameNima M. Farzan
                                                         Division of
Corporation Finance
Comapany NameKinnate Biopharma Inc.
                                                         Office of Life
Sciences
October 22, 2020 Page 2
cc:       Tony Jeffries, Esq.
FirstName LastName